Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Maribavir antagonizes the antiviral action of ganciclovir on human cytomegalovirus.

Literature DB >> 17005835

Maribavir antagonizes the antiviral action of ganciclovir on human cytomegalovirus.

Abstract

The cytomegalovirus (CMV) UL97 kinase inhibitor maribavir antagonized the anti-CMV effect of ganciclovir, increasing the ganciclovir 50% inhibitory concentration against a sensitive strain by up to 13-fold. Antiviral activities of foscarnet and cidofovir were unaffected by maribavir.

Entities: Chemical Species

Mesh：

Substances：

Year: 2006 PMID： 17005835 PMCID： PMC1610080 DOI： 10.1128/AAC.00577-06

Source DB: PubMed Journal: Antimicrob Agents Chemother ISSN： 0066-4804 Impact factor: 5.191

11 in total

1. EUCAST Definitive Document E.Def 1.2, May 2000: Terminology relating to methods for the determination of susceptibility of bacteria to antimicrobial agents.

Authors:
Journal: Clin Microbiol Infect Date: 2000-09 Impact factor: 8.067

2. Mutations in the human cytomegalovirus UL27 gene that confer resistance to maribavir.

Authors: Sunwen Chou; Gail I Marousek; Anne E Senters; Michelle G Davis; Karen K Biron
Journal: J Virol Date: 2004-07 Impact factor: 5.103

3. Phenotyping of cytomegalovirus drug resistance mutations by using recombinant viruses incorporating a reporter gene.

Authors: Sunwen Chou; Laura C Van Wechel; Heather M Lichy; Gail I Marousek
Journal: Antimicrob Agents Chemother Date: 2005-07 Impact factor: 5.191

4. Effect of cell culture conditions on the anticytomegalovirus activity of maribavir.

Authors: Sunwen Chou; Laura C Van Wechel; Gail I Marousek
Journal: Antimicrob Agents Chemother Date: 2006-07 Impact factor: 5.191

5. Cytomegalovirus UL97 phosphotransferase mutations that affect susceptibility to ganciclovir.

Authors: Sunwen Chou; Rachel H Waldemer; Anne E Senters; Kevin S Michels; George W Kemble; Richard C Miner; W Lawrence Drew
Journal: J Infect Dis Date: 2001-12-17 Impact factor: 5.226

6. Analysis of the UL97 phosphotransferase coding sequence in clinical cytomegalovirus isolates and identification of mutations conferring ganciclovir resistance.

Authors: S Chou; A Erice; M C Jordan; G M Vercellotti; K R Michels; C L Talarico; S C Stanat; K K Biron
Journal: J Infect Dis Date: 1995-03 Impact factor: 5.226

7. Amino acids of conserved kinase motifs of cytomegalovirus protein UL97 are essential for autophosphorylation.

Authors: D Michel; S Kramer; S Höhn; P Schaarschmidt; K Wunderlich; T Mertens
Journal: J Virol Date: 1999-10 Impact factor: 5.103

8. Potent and selective inhibition of human cytomegalovirus replication by 1263W94, a benzimidazole L-riboside with a unique mode of action.

Authors: Karen K Biron; Robert J Harvey; Stanley C Chamberlain; Steven S Good; Albert A Smith; Michelle G Davis; Christine L Talarico; Wayne H Miller; Robert Ferris; Ronna E Dornsife; Sylvia C Stanat; John C Drach; Leroy B Townsend; George W Koszalka
Journal: Antimicrob Agents Chemother Date: 2002-08 Impact factor: 5.191

9. Interactions among antiviral drugs acting late in the replication cycle of human cytomegalovirus.

Authors: David L Evers; Gloria Komazin; Dongjin Shin; Debbie D Hwang; Leroy B Townsend; John C Drach
Journal: Antiviral Res Date: 2002-10 Impact factor: 5.970

10. Interactions of 1263W94 with other antiviral agents in inhibition of human cytomegalovirus replication.

Authors: Dean W Selleseth; Christine L Talarico; Teresa Miller; Michael W Lutz; Karen K Biron; Robert J Harvey
Journal: Antimicrob Agents Chemother Date: 2003-04 Impact factor: 5.191

26 in total

Review 1. Progress in the development of new therapies for herpesvirus infections.

Authors: Nathan B Price; Mark N Prichard
Journal: Curr Opin Virol Date: 2011-12 Impact factor: 7.090

Review 2. Viral serine/threonine protein kinases.

Authors: Thary Jacob; Céline Van den Broeke; Herman W Favoreel
Journal: J Virol Date: 2010-11-17 Impact factor: 5.103

Review 3. The search for new therapies for human cytomegalovirus infections.

Authors: Mark N Prichard; Earl R Kern
Journal: Virus Res Date: 2010-11-21 Impact factor: 3.303

Review 4. How we treat cytomegalovirus in hematopoietic cell transplant recipients.

Authors: Michael Boeckh; Per Ljungman
Journal: Blood Date: 2009-03-18 Impact factor: 22.113

Review 5. Cytomegalovirus antivirals and development of improved animal models.

Authors: Alistair McGregor; K Yeon Choi
Journal: Expert Opin Drug Metab Toxicol Date: 2011-09-01 Impact factor: 4.481

6. Advances in the Development of Therapeutics for Cytomegalovirus Infections.

Authors: Edward Acosta; Terry Bowlin; Jennifer Brooks; Lillian Chiang; Islam Hussein; David Kimberlin; Lawrence M Kauvar; Randi Leavitt; Mark Prichard; Richard Whitley
Journal: J Infect Dis Date: 2020-03-05 Impact factor: 5.226

7. Inhibition of cellular STAT3 synergizes with the cytomegalovirus kinase inhibitor maribavir to disrupt infection.

Authors: Justin M Reitsma; Scott S Terhune
Journal: Antiviral Res Date: 2013-09-23 Impact factor: 5.970

8. How I treat resistant cytomegalovirus infection in hematopoietic cell transplantation recipients.

Authors: Firas El Chaer; Dimpy P Shah; Roy F Chemaly
Journal: Blood Date: 2016-10-19 Impact factor: 22.113

Review 9. Antiviral drug resistance: mechanisms and clinical implications.

Authors: Lynne Strasfeld; Sunwen Chou
Journal: Infect Dis Clin North Am Date: 2010-06 Impact factor: 5.982

10. Accelerated evolution of maribavir resistance in a cytomegalovirus exonuclease domain II mutant.

Authors: Sunwen Chou; Gail I Marousek
Journal: J Virol Date: 2007-10-17 Impact factor: 5.103